John C. Byrd

机构：The Ohio State University, University of Cincinnati · ORCID：0000-0001-9830-0711

发表论文 1348 篇 · 总被引 65116 次 · h-index 118

代表论文

Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib (2024 · Blood · 被引 47)
Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN (2025 · Blood · 被引 43)
Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1 -Mutated or KMT2A -Rearranged AML (2025 · Journal of Clinical Oncology · 被引 36)
Beat-AML 2024 ELN–refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy (2024 · Blood Advances · 被引 29)
LP-118 is a novel B-cell lymphoma 2 / extra-large inhibitor that demonstrates efficacy in models of venetoclaxresistant chronic lymphocytic leukemia (2024 · Haematologica · 被引 13)
LP-168 (Rocbrutinib), a Novel Covalent and Non-Covalent Next-Generation Inhibitor of Bruton's Tyrosine Kinase: Updates on the Phase 1 Trial and Initial Results of the CLL Gatekeeper Mutation Cohort (2024 · Blood · 被引 8)